2 completed. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Parke-Davis: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CI-994 in Treating Patients With Advanced Myeloma CI-994 - Multiple Myeloma | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 6 | 1997-08-01 | 2012-09-25 |
| TART - Troglitazone Atherosclerosis Regression Trial troglitazone - Atherosclerosis, Diabetes Mellitus | Phase 2 / Phase 3 | Completed | Parke-Davis | 288 | 1997-01-01 | 2009-12-11 |
Atherosclerosis (1) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Insulin Resistance (1) · Multiple Myeloma (1) · Neoplasms, Plasma Cell (1)
Histone Deacetylase Inhibitors (1) · Troglitazone (1) · tacedinaline (1)
United States (2)
Howard N. Hodis, MD (1) · Melissa Alsina, M.D. (1)